Polar Capital’s Protagonist Therapeutics PTGX Stock Holding History

Polar Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,000	Closed	-$1.04M	–	274
2017 Q4	$1.04M	Sell	50,000 -100,000	-67%	-$1.77M	0.01%	245
2017 Q3	$2.65M	Buy	150,000 +50,000	+50%	+$692K	0.03%	219
2017 Q2	$1.13M	Buy	100,000 +75,000	+300%	+$802K	0.02%	227
2017 Q1	$320K	Buy	+25,000	New	+$403K	﹤0.01%	251

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Polar Capital's PTGX Position: Q1 2018 in Review

Polar Capital sold out of Protagonist Therapeutics (PTGX) in Q1 2018, closing a stake of 50,000 shares — an estimated $1.04M sold.

Polar Capital first reported a position in PTGX in Q1 2017 and held it in 4 quarters. The position peaked at $2.65M in Q3 2017. 70 funds tracked by Wall St. Rank hold PTGX as of Q1 2018.

Polar Capital reported no remaining Protagonist Therapeutics position as of Q1 2018 after selling out during the quarter.
Polar Capital sold 50,000 Protagonist Therapeutics shares in Q1 2018, an estimated $1.04M.
Polar Capital first reported a position in Protagonist Therapeutics in Q1 2017 and held it in 4 quarters.
Polar Capital's Protagonist Therapeutics position peaked at $2.65M in Q3 2017.
70 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2018.

Based on Polar Capital's 13F filing for Q1 2018, filed 15 May 2018.